STOCK COMPARISON
Lotus Health Group vs Nestle India: Fair Value & Quality
Both stocks run through our valuation models. Here is how Lotus Health Group (600186) and Nestle India (NESTLEIND) compare, as of Aug 10, 2026.
As of Aug 10, 2026, Fair Value Calculator sees Lotus Health Group as the less overvalued of the two: Lotus Health Group trades at ¥9.89 versus a fair value of ¥3.47 (-65%), while Nestle India trades at ₹1,540 versus ₹362 (-76%).
Lotus Health Group
600186.SHG · CNY · Consumer Staples
-65%
upside to fair value
overvalued
Price¥9.89
Fair Value¥3.47
Quality62/100
Nestle India
NESTLEIND.NSE · INR · Consumer Staples
-76%
upside to fair value
overvalued
Price₹1,540
Fair Value₹362
Quality72/100
Head-to-head numbers
Green value = the better side for that row (for valuation multiples: lower = cheaper).
Lotus Health GroupNestle India
Valuation
45.6×P/E (TTM)78.9×
4.67×P/S (TTM)11.91×
8.75×P/B—
26.1×EV/EBITDA53.1×
0.84×PEG—
—Dividend yield0.8%
—Dividend per share₹12.00
Profitability
10%Net margin15%
18%Operating margin23%
20%Return on equity76%
9%Return on assets23%
Growth
28%Revenue growth (YoY)23%
26.9%Avg. growth/yr (3Y)11.3%
15.8%Avg. growth/yr (5Y)11.7%
Balance & size
0.09×Debt / equity0.00×
$3BMarket cap$29B
healthyGrowth qualityhealthy
Lotus Health Group leads: 6 to 5 metric wins.
Dash = not meaningfully computable, for example with negative equity.
Quality in detail
The quality score, broken down into the same factor families as on the stock page, 0 to 100 per family.
Lotus Health Groupof which business quality 61 · market factors 74
Nestle Indiaof which business quality 73 · market factors 78
ProfitabilityMargins and returns on capital today
56
93
Quality GrowthAre margins and returns improving?
88
50
CashflowEarnings quality: real cash, not paper profit
46
75
Fin. StrengthBalance sheet, leverage, solvency risk
93
76
InvestmentDisciplined investing over empire-building
57
42
Low VolatilityCalm price path (market factor)
50
93
MomentumPrice trend over the last 3–12 months (market factor)
92
62
52W MomentumDistance to the 52-week high (market factor)
72
88
Net IssuanceBuybacks instead of dilution
23
82
What the models say
The median fair value (base case) per model family, each in the currency of its trading venue. Green = above the current price, red = below.
Lotus Health Group
DCF Models¥3.54
Earnings-Based¥2.53
Dividend Discount¥0.25
Multiples¥3.67
Asset-Based¥0.73
Growth DCF¥3.00
Economic Profit¥2.48
Growth Earnings¥2.87
25 of 25 models see the stock below the current price.
Nestle India
DCF Models₹451
Earnings-Based₹208
Dividend Discount₹229
Multiples₹278
Asset-Based₹17.92
Growth DCF₹402
Economic Profit₹198
Growth Earnings₹324
26 of 26 models see the stock below the current price.
Scenario ranges
From our cautious bear case to the optimistic bull case. The white tick is the current price: left of fair value means room to run.
Lotus Health Group
Bear ¥2.53Fair Value ¥3.47Bull ¥4.53
¥9.89 = current price (white tick)
Nestle India
Bear ₹273Fair Value ₹362Bull ₹452
₹1,540 = current price (white tick)
Compare two other stocks
Tap a field and type again, ticker or company name.
Ranked within their sector
Where each stock sits within its sector peer group. Band = middle 50% of peers, tick = median, dot = this stock.
Lotus Health Group · Consumer Staples
Quality score62 · above median
Fair value upside-65% · bottom 25%
Nestle India · Consumer Staples
Quality score72 · Top 25%
Fair value upside-76% · bottom 25%
Bottom line
As of Aug 10, 2026, Fair Value Calculator sees Lotus Health Group as the less overvalued of the two: Lotus Health Group trades at ¥9.89 versus a fair value of ¥3.47 (-65%), while Nestle India trades at ₹1,540 versus ₹362 (-76%).
Nestle India has the higher quality score (72/100).
See the full analysis →
More comparisons
Popular match-ups from the same sectors, all with fair value and quality score.
Free · Top-25 report
See the undervalued quality stocks every month
Just your email for the monthly Top-25 report of the most undervalued quality stocks, with fair value, quality and price target. Plus 14 days of Pro to try, no card.
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click. Not financial advice.
A model-based valuation snapshot from 21 models. Values change with price and fundamentals; the date shown above applies.
